Regulus Appoints VP, Clinical Development
This article was originally published in Scrip
Regulus Therapeutics Inc., a biopharmaceutical company developing innovative medicines targeting microRNAs, has appointed Dr. Michael Huang vice-president of clinical development. At Regulus, Huang will be responsible for leading the company's global clinical operations and medical affairs and will serve as a key member of the executive leadership team. Most recently, Huang was vice-president of clinical development at Auspex Pharmaceuticals, Inc. (acquired by Teva Pharmaceutical Industries Ltd. in May 2015) and was responsible for providing project and clinical leadership across multiple programs focused on the treatment of central nervous system disorders.
You may also be interested in...
Crystal ball gazing is a tricky, sometimes futile, endeavor. No one knows what the future holds, but there are consistent scenarios emerging that are being debated by industry leaders as they try to foretell and outsmart key market catalysts expected to ripple across the biopharma sector in 2020. With insights from executives, investors and consultancies, as well as our own experts, In Vivo can paint a picture of biopharma wins and woes expected in the new year and new decade.
Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients.
Dmitry Kuzmin, managing partner, and Owen Smith, investment director, talk to In Vivo about 4BIO’s approach to venture investing in the biopharma sector: successes, red flags and targets for its second fund.